GTP Bioways Group is a French company operating as a biotech CDMO (contract development and manufacturing organization), specializing in R&D services, process development, and production of monoclonal antibodies (mAbs), enzymes, proteins, nanodrugs, antibody drug conjugates (ADCs), and fill & finish. GTP Bioways Group, with multiple locations across France, specializes in delivering comprehensive services to biopharmaceutical companies. From preclinical development to commercial stages, the group focuses on utilizing cutting-edge technologies to advance innovative therapies.  

GTP Bioways Group’s services are seamlessly integrated with those of the Olon Biotech Division. This integration enables Olon Biotech to expand and diversify its technological offerings, supporting every stage of the lifecycle, from R&D and preclinical phases to industrialization, through microbial and mammalian fermentation, and biotherapeutics. Additionally, Olon Biotech provides comprehensive services for the development and production of innovative ADC classes, offering a complete solution from mAbs to linkers, to payloads, to conjugation, and to fill & finish processes. 

GTP Bioways operates a total of four sites in France (Toulouse, Labège, Veyre-Monton, and Saint-Julien-en-Genevois) focused on development, clinical trial and cGMP manufacturing. The headquarters are based in Toulouse.  

The four centers operate according to the highest quality standards, in line with reference GMPs and are regularly inspected by the relevant regulatory authorities. 

The business areas on which GTP Bioways focuses include biologics manufacturing and ADC manufacturing (using mammalian and microbial fermentation technology), nanodrug manufacturing, fill and finish, and analytical development, including host-cell proteins (HCP) and immuno assays. In particular, the company has consolidated a strong expertise in the business areas in which it operates. Evidenced by a significative number of successfully developed biological processes, the management of a broad and diversified range of expression systems (mammalian, bacterial, yeast, insect cells) and molecules (mAbs, antibody fragments, cytokines, fusion proteins, enzymes, antigens). In addition, the group possesses significant expertise in bioconjugation and fill & finish. The CDMO services offered make up an integrated platform capable of supporting customers from drug discovery, through the entire development process with a special focus on the pre-clinical phase, Phase I,  and Phase II. 

GTP Group’s service offering is perfectly integrated with those of the Olon Biotech Division. The Olon Biotech Division offers CDMO services as well as the development, production, and sale of proprietary products. The “heart” of the division are the two biotechnology centers of excellence in Settimo Torinese and Capua (Italy). GTP Group’s specific capabilities in fully supporting CDMO biotechnology projects also in the early phase of new molecule development (preclinical, Phase I and Phase II), perfectly complements Olon’s current assets, so as to enrich and broaden the offering to customers. By virtue of this integration, Olon Biotech will be able to support every stage of development, from preclinical to industrialization by large-scale microbial fermentation.  

In Q3 2024, Olon will finalize its €25-million investment in a facility operating under extremely high containment, fully dedicated to the development and the production of ultra high-potent APIs (payloads and payload-linkers for ADCs.  

Olon relies on more than four decades of experience in manufacturing cytotoxic products. 

With the acquisition of GTP, Olon Biotech will be able to offer full services for the development and production of ADCs, capable of supplying everything from mAbs to linkers, payloads, conjugation, and fill & finish. 

“The ADC class is highly promising and extremely challenging as well, as it requires specific capabilities to handle different modalities with strict containment regulations. This required high level of control ensures the safest environment for ADC payload–linker production and product integrity, which can only be reached by leveraging decades of expertise in containment for cytotoxic anticancer production, focusing on full control of cross-contamination, operator protection, and extensive training” commented Paolo Tubertini, CEO of the Olon Group. 

“The acquisition of GTP Bioways Group implies a strong and significant strengthening of Olon’s service pipeline with the aim of creating new business opportunities, acquiring new customers and high-potential market areas, and ultimately continuing the company’s growth” stated Olon’s Tubertini.  

Since its founding, Olon Group has always pursued a strategy of growth, consolidation and expansion in the global market both internally and externally through acquisitions. The strategy has yielded significant results, with a track record since 2003 of 12 acquisitions of companies operating in the pharmaceutical chemicals sector, both domestic and international, which have been successfully acquired and integrated and are now an integral part of the Group’s extensive and diversified global production network, operating both by chemical synthesis and microbial fermentation (biotechnology). The different businesses acquired have all provided expertise that has collectively enriched the company’s technological offering, increasing its competitiveness. In full continuity with this strategy, and with the aim of pursuing a further step forward in terms of expansion and growth in new technologies and services to offer its customers, Olon acquired GTP Group. 

In line with this strategy and aiming to advance its innovative and high-tech offerings to customers, Olon has acquired GTP Bioways Group. GTP Bioways Group’s specific capabilities in fully supporting CDMO biotechnology projects also in the early phase of new molecule development (preclinical, Phase I and Phase II), perfectly complements Olon’s current assets, to enrich and broaden its offering to customers.